Factors predictive of response to growth hormone therapy in Turner's syndrome. 1997

P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
Department of Paediatrics, University of Auckland, New Zealand.

In Turner's syndrome there is marked heterogeneity of growth response to growth hormone (GH) therapy. The study aim was to identify pretreatment factors that influence response to GH therapy. The 70 subjects recruited were prepubertal, had not received sex steroids and had received 28 units/m2/week of GH for > or = 1 year. Pretreatment variables associated with the greatest improvement in height SDS (r2 = 0.58) were weight for length index (p = 0.0001), target height (p = 0.004), bone age delay (p = 0.008) and age (p = 0.04). In conclusion, during two years of GH therapy the best growth response occurred in girls who were younger, heavier, had a delayed bone age and tall parents. Height SDS as a continuous variable is the most effective measure of growth when considering pretreatment factors that may influence response to GH therapy.

UI MeSH Term Description Entries
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006128 Growth Gradual increase in the number, the size, and the complexity of cells of an individual. Growth generally results in increase in ORGAN WEIGHT; BODY WEIGHT; and BODY HEIGHT.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000365 Age Determination by Skeleton Establishment of the age of an individual by examination of their skeletal structure. Bone Age Measurement,Skeletal Age Measurement,Skeletal Maturation Index,Age Measurement, Bone,Age Measurement, Skeletal,Age Measurements, Bone,Age Measurements, Skeletal,Bone Age Measurements,Index, Skeletal Maturation,Indices, Skeletal Maturation,Maturation Index, Skeletal,Maturation Indices, Skeletal,Measurement, Bone Age,Measurement, Skeletal Age,Measurements, Bone Age,Measurements, Skeletal Age,Skeletal Age Measurements,Skeletal Maturation Indices
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D014424 Turner Syndrome A syndrome of defective gonadal development in phenotypic females associated with the karyotype 45,X (or 45,XO). Patients generally are of short stature with undifferentiated GONADS (streak gonads), SEXUAL INFANTILISM, HYPOGONADISM, webbing of the neck, cubitus valgus, elevated GONADOTROPINS, decreased ESTRADIOL level in blood, and CONGENITAL HEART DEFECTS. NOONAN SYNDROME (also called Pseudo-Turner Syndrome and Male Turner Syndrome) resembles this disorder; however, it occurs in males and females with a normal karyotype and is inherited as an autosomal dominant. Bonnevie-Ullrich Syndrome,Gonadal Dysgenesis, 45,X,Gonadal Dysgenesis, XO,Monosomy X,Status Bonnevie-Ullrich,Turner's Syndrome,Ullrich-Turner Syndrome,Bonnevie Ullrich Syndrome,Status Bonnevie Ullrich,Syndrome, Ullrich-Turner,Turners Syndrome,Ullrich Turner Syndrome,XO Gonadal Dysgenesis

Related Publications

P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
June 1992, Irish medical journal,
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
January 1987, Hormone research,
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
October 1988, Endocrinologia japonica,
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
January 1989, Acta paediatrica Scandinavica. Supplement,
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
January 1986, Hormone research,
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
January 1995, Acta paediatrica (Oslo, Norway : 1992),
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
December 1969, JAMA,
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
July 1991, Acta endocrinologica,
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
January 1980, Osaka city medical journal,
P Hofman, and W S Cutfield, and E M Robinson, and A Clavano, and G R Ambler, and C Cowell
November 1991, Harefuah,
Copied contents to your clipboard!